The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status

C. Doglioni, A. Dei Tos, L. Laurino, C. Chiarelli, M. Barbareschi, G. Viale

Research output: Contribution to journalArticle

Abstract

BCL-2 protein plays a pivotal role in overriding programmed cell death (apoptosis), thus favouring a prolonged survival of normal and neoplastic cells. Expression of the bcl-2 gene has been documented in some human tumours (non-Hodgkin's lymphomas and prostatic adenocarcinomas), but findings in breast carcinomas have not been reported. We have used the monoclonal antibody 124 to investigate BCL-2 expression in 212 breast carcinomas, and to correlate it with the oestrogen (ER), progesterone (PR) and epidermal growth factor receptor (EGFR) status, and with other clinicopathological variables including tumour type, grade, stage, growth fraction (as evaluated by Ki-67 immunostaining), and p53 accumulation. Of the 212 carcinomas, 173 (81.6%) exhibited BCL-2 immunoreactivity in more than 25% of the neoplastic cells. BCL-2 immunoreactivity was strongly correlated with ER and PR expression (P

Original languageEnglish
Pages (from-to)47-51
Number of pages5
JournalVirchows Archiv
Volume424
Issue number1
DOIs
Publication statusPublished - Jan 1994

Keywords

  • BCL-2 immunoreactivity
  • Breast carcinoma
  • Oestrogen receptors
  • p53 accumulation
  • Progesterone receptors

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status'. Together they form a unique fingerprint.

  • Cite this